What it is
Survodutide acts on two receptors, glucagon and GLP-1, and is injected under the skin once a week in trials2. GLP-1 is a hormone your gut releases when you eat12, and glucagon is a hormone that raises blood sugar. In animal studies, it lowered body weight both by cutting how much was eaten and by raising how much energy the body burned6. In mice, its effect on appetite appeared to run through the GLP-1 receptor6. It's also being tested for an advanced form of fatty liver disease called MASH (metabolic dysfunction-associated steatohepatitis)75. Fatty liver disease, where too much fat builds up in the liver, is also called MASLD7.
What makes it distinct
Its phase 3 program covers weight, MASH and type 2 diabetes1.
What the evidence shows
Two 76-week phase 3 trials, published in 2026, compared weekly survodutide with a placebo23. In SYNCHRONIZE-1, 725 adults with obesity, or overweight and a related health problem, who didn't have diabetes took part; people on survodutide lost more weight than people on placebo2. SYNCHRONIZE-2 enrolled 752 adults with overweight or obesity and type 2 diabetes, with the same kind of result, and their HbA1c, a blood test of average blood sugar, fell more than on placebo3. In SYNCHRONIZE-MASLD, 216 adults with obesity and fatty liver disease with signs of inflammation or scarring took it or a placebo for 48 weeks4. More people on survodutide reached the trial's target drop in liver fat, measured by MRI scan, and they lost more weight4. That trial recruited only in the United States and Spain4. An earlier phase 2 trial in 293 adults with MASH and liver scarring, confirmed by biopsy (a small sample of liver tissue), found MASH improved without scarring getting worse in more people on survodutide than on placebo5. Stomach and gut side effects were the most common, mostly mild to moderate, and happened more often than on placebo23. Boehringer Ingelheim, which is developing it under a license from Zealand Pharma, funded SYNCHRONIZE-1, SYNCHRONIZE-2 and the phase 2 MASH trial1235.
Open questions
- Heart safety. SYNCHRONIZE-CVOT, a trial in 5,531 people, has finished9. In October 2026, Zealand Pharma said Boehringer expects to present the results later in 20261.
- Whether it improves liver scarring and prevents liver problems over time. The LIVERAGE and LIVERAGE-Cirrhosis phase 3 trials in MASH are still recruiting10111.
- Effects beyond 76 weeks, the length of its phase 3 weight trials23.
Worth knowing
For MASH with moderate or advanced liver scarring (fibrosis), the FDA gave it Breakthrough Therapy designation in September 20241. The FDA describes this as a process meant to speed up the development and review of drugs for serious conditions8. It isn't an approval1.
Sources
- Zealand Pharma company announcement No. 52/2026 (1 October 2026): Boehringer Ingelheim reports SYNCHRONIZE-2 results for survodutide
- Survodutide Once Weekly for the Treatment of Adults with Obesity (SYNCHRONIZE-1). N Engl J Med 2026
- Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes (SYNCHRONIZE-2). N Engl J Med 2026
- Survodutide in adults with obesity and MASLD: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med 2026
- A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. N Engl J Med 2024
- Survodutide acts through circumventricular organs in the brain and activates neuronal regions associated with appetite regulation. Mol Metab 2026
- How does survodutide work? Plain language review of a potential new medication for obesity and liver disease. Ther Adv Gastroenterol 2026
- FDA: Breakthrough Therapy
- ClinicalTrials.gov NCT06077864: Survodutide (BI 456906) cardiovascular safety in people with overweight or obesity (SYNCHRONIZE-CVOT)
- ClinicalTrials.gov NCT06632444: LIVERAGE, survodutide in NASH/MASH with moderate or advanced fibrosis
- ClinicalTrials.gov NCT06632457: LIVERAGE-Cirrhosis, survodutide in NASH/MASH with cirrhosis
- Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018 (PubMed 29617641)
More in GLP-1 and glucagon drugs